



	Questions : Lok Sabha




























Screen Reader Access
Skip to Main Content
Skip to Navigation



Text Size

                                A

                                A
A















हिन्दी मे








Parliament of India Lok Sabha House of the
                        People






* Special Characters not allowed












India Time 


Your Time 


                        Tuesday,
                        12 April 2022









HomeMembersSitting MembersMembers Home PageMembers' PortalContact DetailsMembers SearchStatistical AnalysisAttendance of MembersHandbook Members Since 1952Digitized Who's WhoOthers BusinessProvisional CalendarList of BusinessPapers to be LaidList of Private Members' BusinessBulletin-IDigitized Lok Sabha Bulletin Part IBulletin-IIStatement of WorkSpecial Mentions (ZERO HOUR)Resume of WorkDigitized Resume of Work done by Lok Sabha QuestionsHomeQuestion ListStatus of notices of questionQuestions CalendarGrouping of Ministries - AlphabeticalOfficers in Min./Dept. Dealing with Parliamentary WorkQuestion SearchSupplementary Questions DebatesIntroductionSynopsisUncorrected DebateText of DebateDigitized DebatesConstituent Assembly DebatesWit And HumourDebate SearchHindi FontsDisclaimer Papers LaidPapers Laid on the Table of the House LegislationIntroduction(How Bill Becomes Act)Bills IntroducedBills PassedBills PendingBills AssentedBills LapsedBills WithdrawnBills NegativedBills Search Disclaimer CommitteesIntroductionChairpersonSummary of WorkCommittee Meetings ScheduleBills Referred to CommitteesReports PresentedDigitized ReportsPress ReleaseMembership SearchToday's Committee MeetingsCommittee Subject SelectedDepartment Related-RS Govt. AssurancesSANSAD TVIntranet





HomeQuestion ListStatus of notices of questionQuestions CalendarGrouping of Ministries - AlphabeticalOfficers in Min./Dept. Dealing with Parliamentary WorkQuestion SearchSupplementary Questions











Download as PDF




Print












PDF/WORD(Hindi)


PDF/WORD




                                    GOVERNMENT OF INDIA
                                





                                    MINISTRY OF
                                    COMMERCE AND INDUSTRY






                                    LOK SABHA
                                





UNSTARRED 


                                    QUESTION NO:
                                

29






                                    ANSWERED ON: 
                                

02.02.2022






API Manufacturers




Unmesh Bhaiyyasaheb Patil













                                                    Sujay Radhakrishna Vikhepatil
                                                








                                                    Heena Vijaykumar Gavit
                                                








                                                    Aparupa  Poddar
                                                








                                                    Rajendra Dhedya  Gavit
                                                








                                                    Krishna Pal Singh Yadav
                                                








                                                    Shrikant Eknath Shinde
                                                












                        Will the Minister of





COMMERCE AND INDUSTRY


                        be pleased to state:-















                                                    (a) the details of policies and schemes to bolster the Active Pharma Ingredients (API) manufacturers in India; (b) the details of funds allocated, sanctioned and disbursed during the past five years for the purpose, State/Union Territory-wise, specially in the State of Maharashtra, West Bengal and Madhya Pradesh; (c) the details of API production State-wise and the manner in which the schemes, policies and funds allocated have bolstered the manufacturing of API during the past five years; (d) the details of the mechanism for imposing subsequent duties on competitive market along with the projected benefits to the API manufacturers; and (e) the details of any other changes being stipulated for improving the status of API manufacturers, State/ Union Territory-wise, specially in the State of Maharashtra, West Bengal and Madhya Pradesh?






ANSWER




                                                        THE MINISTER OF STATE IN THE MINISTRY OF COMMERCE AND INDUSTRY(SMT. ANUPRIYA PATEL)(a)	to (e):   India is the third largest player globally in Pharmaceuticals in terms of volume and is the largest supplier of low cost generics and vaccines to the world.  The Government is also taking steps in the form of various schemes to attract investments in pharmaceuticals and medical devices sectors, including for the Active Pharma Ingredients (API) manufacturing. The details of the scheme bolstering  the Active Pharma Ingredients (API) manufacturers in India is at Annexure.ANNEXUREAnnexure to Lok Sabha Unstarred Question No.29 to be answered on 02.02.2022 .(i) Production Linked Incentive Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates (DIs)/ Active Pharmaceutical Ingredients (APIs) in India.•	The Union Cabinet approved the scheme on 20.03.2020 with the objective to boost domestic manufacturing of identified KSMs, DIs and APIs.The tenure of the scheme is from FY 2020-21 to 2029-30, with the total financial outlay of Rs. 6,940 crores. •	The Financial incentive under the sub-scheme is provided on sales of 41 identified products categorized into four Target Segments. (ii)   PLI Scheme for Pharmaceuticals: -•	Eligible drugs under this scheme approved on 24.02.2021 include Active Pharmaceutical Ingredients among other categories of pharmaceutical products. The Operational Guidelines have been issued on 1.6.2021. •	The total financial outlay of the scheme is Rs. 15,000 crore and the tenure of the scheme is from FY 2020-2021 to 2028-29.  (iii)     Scheme for Promotion of Bulk drug parks•	The scheme of “Promotion of Bulk Drug Parks” approved on 20th March, 2020. The scheme provides for support to establish three (03) Bulk Drug Parks for creation of world class Common Infrastructure Facilities (CIF). Guidelines of the scheme were notified on 27th July 2020.•	The total financial outlay of the scheme is Rs. 3000 crores. The tenure of the scheme is from FY 2020-2021 to FY 2024-2025. *****
























HomeArchiveIndex to Select Questions (1984-1999)Ballot ListStatistical Statements Relating to QuestionsUploading of Questions - Status QueryProcedure for Sending Text of Questions & AnswersDemarcation of responsibilities in Govt. of IndiaBrochure on Statutory Corporations, Companies and Other Bodies in Which the Government of India have financial or controlling interestHighlights pertaining to questions of 17th Lok Sabha






Contact Us 
Disclaimer











        Developed and Hosted by National Informatics Centre (NIC)

Content on this website is published,
            managed & maintained by Software Unit, Computer (HW & SW) Management. Branch,
            Lok Sabha Secretariat





HomeMembersBusinessQuestionsDebatesPapers Laid


LegislationCommitteesSANSAD TVIntranetSecretariatPRIDE


RecruitmentSC/ST ReservationConferenceParliament Library


About ParliamentPhoto GalleryRelated LinksRTITendersFAQ


SpeakerDy. SpeakerLeader of the HousePanel of ChairpersonsContact UsFeedback


Council of MinistersPublications of MinistriesParliamentry ProceduresJournal of Parliamentary Information
Visitor's Counter:113251975







Copyright
Privacy Policy
Disclaimer
Terms &
                Conditions

                Accessibility Statement
Accessibility
                Options
Feedback
Site Map







